Was LTBI Ever Treated with a Single Daily Pill in the Early 2000s?
Yes, your patient's report is entirely consistent with standard LTBI treatment from that era—she almost certainly received isoniazid (INH) 300 mg daily for 6 months, which was a single-pill regimen widely used and recommended at that time.
Historical Context and Treatment Standards
In the early 2000s, the standard LTBI treatment options included 1:
- Isoniazid daily for 6-9 months (the most common regimen)
- Rifampin plus pyrazinamide for 2 months (though this fell out of favor due to hepatotoxicity concerns)
- Rifampin alone for 4 months (as an alternative)
The 6-month daily isoniazid regimen was explicitly recommended in the 2000 ATS/CDC guidelines 1. While 9 months was considered optimal, the guidelines specifically stated that "a 6-mo regimen also provides substantial protection and has been demonstrated to be superior to placebo" and noted that "health departments or other providers may prefer to concentrate efforts in ensuring the implementation of a 6-mo rather than a 9-mo course of isoniazid" 1.
The Single Pill Formulation
Isoniazid was available as a 300 mg single tablet during this period, making it literally "one pill" taken daily. This formulation was standard in many countries, though some regions (like Brazil at that time) only had 100 mg tablets requiring three pills daily 2. The Philippines likely had access to the 300 mg formulation, making your patient's recollection accurate.
Clinical Implications for Your Patient
Given this history:
- She likely completed appropriate LTBI treatment with the 6-month isoniazid regimen
- Her positive QuantiFERON now could represent:
- Persistent immunologic memory from her treated LTBI (most likely)
- New exposure/reinfection since her treatment
- The original infection if treatment was incomplete or ineffective
Key Pitfalls to Avoid
Do not automatically retreat based solely on a positive QuantiFERON if she truly completed 6 months of daily isoniazid. IGRAs remain positive indefinitely in many treated individuals and do not distinguish between active infection, treated LTBI, and current LTBI 3, 4.
Your assessment should focus on:
- Confirming treatment completion (did she actually take 6 months of daily medication?)
- Ruling out active TB (symptoms, chest X-ray, sputum if indicated)
- Assessing new risk factors (recent TB exposure, immunosuppression)
- Evaluating for treatment failure indicators (if she had known exposure to drug-resistant TB)
If she completed treatment and has no new risk factors or evidence of active disease, retreatment is generally not indicated despite the positive QuantiFERON.